XTSX
ASG
Market cap12mUSD
Jul 09, Last price
0.24CAD
1D
4.44%
1Q
-14.55%
Jan 2017
23.68%
IPO
-82.97%
Name
Aurora Spine Corp
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Aurora Spine Corporation, operating through its subsidiary Aurora Spine, Inc., specializes in the development and distribution of advanced, minimally invasive spine fusion systems and related medical devices. The company's diverse product portfolio includes a range of interspinous process lumbar fusion devices, such as the ZIP, ZIP ULTRA, ZIP LP, and ZIP-51 lines, specifically engineered to treat patients suffering from degenerative disc diseases. Additionally, Aurora Spine provides titanium-coated polyether ether ketone (PEEK) interbody cages. These cages are crucial for maintaining proper spacing and stability between spinal vertebrae, thereby encouraging bone growth to achieve successful fusion. Aurora Spine also supplies sterile, titanium plasma spray coated spinal implants designed to promote bone integration. Complementing these, it offers a suite of interbody products such as the EOS, VOX, Echo, Echo SD, and EchoXL series for lumbar applications, and the Discovery system for cervical surgeries. Among its innovations is SOLO, a 3D-printed, stand-alone anterior lumbar interbody fusion device. This integrated plate and spacer system is designed to maintain the spine's natural anatomical alignment while delivering essential support and stability to the spinal column. Another key offering is SiLo, a posterior fusion device specifically developed for the sacroiliac joint. Furthermore, the DEXA-C cervical interbody system stands out as a porous, 3D-printed intervertebral body fusion device. It features customizable low-, mid-, or high-density lattice patterns, allowing for precise matching with individual patient bone quality. Established in 2013, Aurora Spine Corporation has its corporate headquarters situated in Toronto, Canada.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||